July 3, 2024
TOPLINE: Compared with the general population, patients with urticaria had a 49% higher risk of developing cancer in the first year following diagnosis, which decreased to […]
July 2, 2024
The US Food and Drug Administration (FDA) has approved Eli Lilly’s anti-amyloid donanemab (Kisunla) 350 mg/20 mL once-monthly injection for intravenous infusion for adults with early […]
July 2, 2024
Eight commonly used antidepressants have been ranked by their weight gain potential. Results of a large observational study showed small differences in short- and long-term weight […]
July 2, 2024
(Reuters) -The U.S. Food and Drug Administration said on Tuesday it would revoke the regulation that authorized the use of brominated vegetable oil in food items, […]
July 2, 2024
TOPLINE: In patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib reduces the risk for death by 20% compared with placebo, though the […]
July 2, 2024
TOPLINE: Treatment of osteoporosis with denosumab, compared with bisphosphonate therapy, may help prevent progression to type 2 diabetes (T2D) in those at high risk for it. […]
July 2, 2024
European drug authorities have issued recommendations to address ongoing shortages in glucagon-like peptide 1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity. These […]
July 2, 2024
Should a patient with high lipoprotein a, or Lp(a), be started on low-dose aspirin? This is the conundrum facing many physicians and patients, but even getting […]
July 2, 2024
ORLANDO, Florida — What to prioritize first in managing early diabetes? That was the question debated on an expert panel at the American Diabetes Association (ADA) […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482
Next page